Ask about this productRelated genes to: FJX1 Blocking Peptide
- Gene:
- FJX1 NIH gene
- Name:
- four-jointed box kinase 1
- Previous symbol:
- -
- Synonyms:
- FLJ22416, FLJ25593
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-11-21
- Date modifiied:
- 2018-09-27
Related products to: FJX1 Blocking Peptide
Related articles to: FJX1 Blocking Peptide
- Colon adenocarcinoma (COAD) remains a leading cause of cancer-related mortality worldwide, partly due to the lack of robust biomarkers for early diagnosis and accurate prognosis. Glycoproteins play critical roles in tumorigenesis and may serve as promising sources of biomarkers. This study aimed to identify glycoprotein-related candidate diagnostic and prognostic biomarkers for COAD through integrated bioinformatics approaches and experimental validation. Gene expression profiles and clinical information of COAD patients were obtained from The Cancer Genome Atlas database (TCGA). The expression data for genes associated with glycoprotein were retrieved from the UniProt database. Furthermore, we assessed the mRNA expression levels of the glycoprotein FJX1 in COAD and rectal adenocarcinoma tissues through in situ hybridization (ISH) staining using tissue microarrays. A total of 228 glycoprotein-related differentially expressed genes (DEGs) were identified, enriched in the extracellular matrix organization and signaling pathways such as PI3K-Akt and cAMP. Protein-protein interaction (PPI) network analysis revealed 10 hub genes (LIFR, CNTFR, LIF, CSF2, IL1A, CSF3, F2, FGA, FGFR2, INHBA). Survival screening and multivariate Cox regression identified FJX1 as an independent prognostic factor for overall survival after adjusting for age and stage. FJX1 mRNA was significantly overexpressed in COAD tissues compared to normal (p < 0.001), and high FJX1 expression correlated with advanced T stage, M stage, and pathological stage. ISH confirmed elevated FJX1 mRNA in tumors. Immune infiltration analysis further revealed that high FJX1 expression was associated with increased infiltration of M0 macrophages and neutrophils, and decreased resting memory CD4 T cells, suggesting a potential role in shaping the immunosuppressive tumor microenvironment. GSEA revealed significant enrichment of MAPK signaling in high-FJX1 tumors. In conclusion, this study identified 10 glycoprotein-related hub genes as candidate diagnostic biomarkers warranting further validation and established FJX1 as an independent prognostic biomarker for COAD. FJX1 overexpression is associated with tumor progression and may be linked to MAPK signaling as well as immune modulation. These findings provide a foundation for glycoprotein-based biomarker development in COAD. - Source: PubMed
Publication date: 2026/05/18
Liu HaiyunWan LinjingFang Quangang - Intercellular communication is critical for tissue homeostasis, development and immune responses, with its disruption often implicated in various diseases, particularly cancer. Secretory pathway kinases and kinase‑like proteins (SPKKPs) constitute a distinctive enzyme class operating within the luminal secretory pathway or extracellular space, positioning them as pivotal regulators of cellular communication. This review consolidates current insights into the role of SPKKPs, including the FAM20 family, four‑jointed box kinase 1 (FJX1) and others, in orchestrating intercellular interactions through the phosphorylation of secreted proteins, extracellular matrix components and extracellular vesicle (EV) cargo. The molecular mechanisms by which SPKKPs modulate key oncogenic signaling pathways, such as PI3K/AKT, ERK/MAPK and SMAD family member 2, across diverse cancer types are examined. Additionally, their involvement in EV‑mediated signaling, extracellular matrix remodeling and regulation of fundamental biological processes, including development, tissue homeostasis and immune coordination, is explored. The review further addresses SPKKP dysregulation in a range of pathologies, from nervous system tumors to gastrointestinal and reproductive cancers, and discusses emerging therapeutic strategies. These strategies include specific kinase inhibitors, FJX1‑targeted peptide vaccines and innovative approaches targeting exosomes carrying SPKKPs substrates. Ultimately, this work highlights the essential role of SPKKPs in intercellular communication networks and their promising potential as diagnostic biomarkers and therapeutic targets, particularly in cancer. - Source: PubMed
Publication date: 2026/05/08
Geng ZiangGuan ShuDu ShaoqiZhang ShuoHao JiaxinTian SiyuanZhu ChenDu Shaonan - Protein kinases dysregulation is implicated in various cancer-related processes; however, its clinical utility and biological significance in head and neck squamous cell carcinoma (HNSCC) remain incompletely understood. This study aimed to establish a novel prognostic signature using kinase-related genes (KRGs) for prognostic and therapeutic prediction in HNSCC. - Source: PubMed
Publication date: 2026/05/05
Zhang YangLv PinCao GuangruiQi NaYu MiaoWu Yaping - Focused ultrasound, low-intensity focused ultrasound, and microbubble-enhanced sonoporation are examples of ultrasound-based cancer therapies that have shown promise as biophysical modalities for enhancing drug penetration, immunogenic cell death, and targeted delivery of radiopharmaceuticals in solid tumors. The molecular factors controlling ultrasonic therapy receptivity, however, are still not well understood. Because of the significant variability of the tumor microenvironment (TME), colorectal cancer (CRC) necessitates biomarker-guided techniques to enhance ultrasound-based therapy regimens. - Source: PubMed
Publication date: 2026/02/25
Zhang XiaohuiCao XuguangSu XinyaoHu WeiHou ShuoshuoZhou XiaohuaYang HongbaoJi Hongjian - Colon cancer is one of the most prevalent malignant tumors. Accurate evaluation of patient prognosis and optimization of treatment strategies continue to be major research focuses in colon cancer. Based on The Cancer Genome Atlas (TCGA) database, this study is the first to comprehensively analyze the expression, biological roles, and prognosis of itaconate and Hallmark pathway-related genes in colon cancer using bulk transcriptomics, single-cell transcriptomics, and spatial transcriptomics data. Through strict screening in 448 colon cancer patients from TCGA database (training set) and 7 colon cancer prognostic models from the Gene Expression Omnibus (GEO) database (including 1473 cases in the validation set), 10 prognosis-related genes (TIMP1, FJX1, CD36, CXCL1, ETS2, CDKN2A, INHBB, PLEC, TUBB2, and P4HA1) were selected. The optimal prognostic prediction model (Enet [alpha = 0.2]) was constructed and validated, which showed good prognostic predictive value in both the training and validation sets (average C-index > 0.7) and was superior to previous conventional clinical features and 22 prognostic models developed by researchers in the past 4 years. ScRNAseq (GSE225857) and spatial transcriptomics analyses clarified the cell-specific expression and spatial distribution characteristics of these genes in the tumor microenvironment (TME), with high functional scores mainly enriched in epithelial and stromal cells. Tissue microarray (TMA) showed that the high-risk group had higher tumor mutation burden (TMB) and higher expression of immune checkpoint genes, suggesting higher sensitivity to immunotherapy. Drug sensitivity analysis identified four potentially effective drugs, such as sepantronium bromide, which had better effects on high-risk patients. This study provides a theoretical basis and new targets for precise prognosis and stratified treatment of colon cancer. - Source: PubMed
Publication date: 2026/01/10
Zhang TingtingMeng JianchaoWang QingyunZhang PengLi HuiWei HailangChen DenggangBai ChenNair Sujit